ArticleRSC advances2026
Nanoflower-shaped cobalt-metal-organic framework as an oxidase-like nanozyme and 1,2-diaminobenzene as a catalytic substrate for the innovative signal "off-on" aptamer sensing of prostate-specific antigen.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of simple, sensitive, and reliable methods for detecting prostate-specific antigen (PSA) holds significant importance for the early screening and diagnosis of prostate cancer. In this work, a novel signal "off-on" electrochemical aptamer (Apt) sensing platform was constructed for the first time to detect PSA, utilizing a synthesized nanoflower-shaped three-dimensional cobalt-metal-organic framework (Co-MOF) as an oxidase-mimicking nanozyme and employing 1,2-diaminobenzene as the catalytic substrate. In this design, the Co-MOF nanozyme can directly catalyze the oxidation of 1,2-diaminobenzene to generate diaminophenazine (DAP), an electroactive substance, without the need for H
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.